(News Bulletin 247) – Bayer announced Wednesday that it intends to accelerate its development in pharmaceutical products thanks to some innovative breakthroughs in key areas.
The German group, which is today organizing a day of presentations on the theme of research and development (R&D), explains that it wants to focus on four specialties, namely oncology, cardiovascular diseases, neurology and rare diseases, and immunology, in disciplines where he believes there are unmet medical needs.
The laboratory says in particular that it has made good progress in the design of four experimental drugs in the final phase of development, and whose combined sales could potentially exceed 12 billion dollars.
According to Bayer, this amount is largely sufficient to cope with the drop in revenue anticipated in the short and medium term due to the loss of the exclusivity of certain patents.
It highlights in particular the progress of the finerenone program, which has now entered phase III in chronic renal failure, but also of asundexian, which is also in phase III for the prevention of strokes.
In neurodegenerative diseases, Bayer is highlighting the potential of its two platforms BlueRock (cell therapy) and AskBio (gene therapy), which are working in particular on treatments for Parkinson’s disease.
In the field of immunology, which it considers under-invested today, Bayer has created a platform specializing in proteomics and called Vividion which is currently conducting nine programs, in the pre-clinical phase or in clinical development.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
